Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.
about
Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis.Oral delivery of Brucella spp. recombinant protein U-Omp16 abrogates the IgE-mediated milk allergyNanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice.Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammationEngineering virus-like particles as vaccine platformsA 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patientsImmune response to nanomaterials: implications for medicine and literature review.A comparison of immunotherapy delivery methods for allergen immunotherapy.Emerging therapies in allergic conjunctivitis and dry eye syndrome.Food allergy: management, diagnosis and treatment strategies.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Toll-like receptor agonists: a patent review (2011 - 2013).Using viruses as nanomedicines.Investigational drugs for the treatment of allergic rhinitis.Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.Phase II drugs under investigation for allergic conjunctivitis.Biological Modulators in Eosinophilic Diseases.Updating the role played by immunotherapy for allergic rhinitis: meta-analysis.The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook.Antigen delivery by virus-like particles for immunotherapeutic vaccination.Allergen immunotherapy in allergic rhinitis: current use and future trends.Recent advances in the use of nanoparticles for allergen-specific immunotherapy.TLR9-based immunotherapy for the treatment of allergic diseases.Investigational new drugs for allergic rhinitis.The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement.Is The Allergen Really Needed in Allergy Immunotherapy?[Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].[Specific immunotherapy : clinical experience with recombinant molecular major allergens and hypoallergenic variants].Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies.Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients.Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.Development of CpG ODN Based Vaccine Adjuvant Formulations.CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study.JNK-TLR9 signal pathway mediates allergic airway inflammation through suppressing melatonin biosynthesis.
P2860
Q33413438-FFF7E20D-0A33-4E96-9D5D-DF8E27633D26Q34291240-C143C3E7-BA9A-44A7-8765-6E71D275AD6DQ36099185-724992B6-429F-4747-9F4D-BA22DE9E6F2FQ36870120-2C743C55-7176-4E0C-AFE3-92FDDCDCE94BQ37172342-6A97EE02-44C3-4885-8E4E-6E838114FCCAQ37565596-00E849E5-2CC2-4A61-8AA2-39CB9AD9B95FQ38039974-D1B5121D-02EB-4542-B147-2CBF73D6A4E6Q38103286-3191CE1F-CC7A-4D6A-A368-3BB4B0255B6CQ38119024-AD25B166-7E0E-49EC-BAAE-3241CDFB2D29Q38119552-34DA3FCF-863E-4069-A59B-BF4505293745Q38168903-F79F100D-AE9C-4EF0-80A0-EBCE8D40455AQ38181176-95BE8071-55B0-4434-A772-A1DE3188B23CQ38191282-068C395F-ED9D-425F-8EF8-790D8C20290FQ38202695-4EC7B198-3173-4CD8-A332-1A1C4AF35F7DQ38217708-F289EC73-4F64-4DEA-AA0D-90BA4DDD6640Q38234039-BA769AB6-381C-4F0A-997F-120F45C407ADQ38240474-BCFCC882-68D4-4918-819E-E6DF609D033FQ38271427-A091D924-8063-4DFA-9712-342DA06B1C17Q38278145-DA2472AA-3D84-4F36-88CF-5D91B4F9C0CAQ38285854-CC3EEBE9-C9B1-4E7E-A5A1-CF7809FD2C8FQ38680655-2E549420-2301-44CA-A21A-41A00066643FQ38802840-52053C52-C006-4561-9B83-F110750F5873Q39000290-18CC058A-0F51-4627-AEFF-57D2DA20403FQ39111947-9D97B597-33EB-43C6-8516-FE75EF55A0EBQ39444008-6F84BD77-EA74-4D23-AC80-EC05529FFD9FQ42701595-799D4B27-7BB8-4D82-B844-18FD0BAD15B0Q42730811-32FA9624-63DE-4220-A916-C0B741555EA0Q43962396-951B7BDF-4889-45F8-9DE6-E022A6B33D35Q44500848-5EF403F4-CA53-4E89-87FB-58ED23846579Q47370297-C5BEF687-9ABF-4E1A-BE7A-6EE88AEEBF2CQ47713994-BD9B6AFD-FEEF-49D7-96BB-F36FBE738284Q48168829-C19840CC-21F1-4227-84A8-2B8749D721FCQ50656129-C46376EE-1C35-461E-8B94-2970471CB773Q51625277-E9A0682C-1639-4B09-A9AA-7C09A0F550F4Q55029792-8BC3BEAA-BCFB-4F62-9FA4-0A9BC5EFF305
P2860
Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Assessment of clinical efficac ...... unctivitis: a phase IIb study.
@en
Assessment of clinical efficac ...... unctivitis: a phase IIb study.
@nl
type
label
Assessment of clinical efficac ...... unctivitis: a phase IIb study.
@en
Assessment of clinical efficac ...... unctivitis: a phase IIb study.
@nl
prefLabel
Assessment of clinical efficac ...... unctivitis: a phase IIb study.
@en
Assessment of clinical efficac ...... unctivitis: a phase IIb study.
@nl
P2093
P2860
P1476
Assessment of clinical efficac ...... unctivitis: a phase IIb study.
@en
P2093
A Hammann-Haenni
M F Bachmann
W A Renner
P2860
P304
P356
10.1111/J.1365-2222.2011.03783.X
P577
2011-06-14T00:00:00Z